ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2232

Neutralization of Angiopoietin-2 Enhances the Efficacy of Anti-Tumor Necrosis Factor-Alpha Treatment in a Mouse Model of Rheumatoid Arthritis by Decreasing Cellular Infiltration into the Joint and Protecting Bone

Brian Naiman, Sean Turman, William Iverson, Ronald Herbst, Tomas Mustelin and Jane Connor, Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: angiopoietin, Mouse model, osteoclasts and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose:  It has recently been established that >75% of patients on methotrexate and a biologic do not achieve complete remission based on the new definition set by ACR/EULAR in 2011. These findings are supported by recent studies utilizing imaging technology such as PDUS or MRI that have detected “subclinical inflammation” in low disease activity patients that correlates with subsequent radiographic progression. Importantly, while anti-TNF-α therapies reduce neovascularization to some extent, the effect is incomplete. Our hypothesis is that inhibiting angiogenesis beyond that provided by anti-TNF-α therapy will provide tighter control of inflammation leading to greater impact on inhibiting disease progression. The key mediators of angiogenesis are members of the vascular endothelium growth factor (VEGF) and angiopoietin (Ang) families.  Several investigators have reported increased expression of these mediators in the RA and PsA joint when compared to normal or osteoarthritis biopsies. Based on previous work demonstrating efficacy of anti-Ang2 therapy in models of RA, we chose to utilize a combination of anti-Ang2 along with anti-TNF-α to explore this hypothesis.

Methods:  Arthritis was induced by immunization of DBA/1 mice with glucose-6-phosphate isomerase.  Animals were treated with either 10 mg/kg anti-Ang2 antibody, 10 mg/kg anti-TNF-α antibody or a combination of the two beginning 7 days following immunization.  Clinical scores were assessed daily.  Animals were terminated 15 days following immunization and joints were evaluated for histological changes (H&E), CD31 staining for endothelial cells, F4/80 staining for macrophages and Cathepsin K for osteoclasts. In addition, selected joints were evaluated for bone cortical roughness around the joints using magnetic resonance imaging.

Results:  Treatment with an anti-Ang2 antibody in addition to an anti-TNF-α antibody resulted in improved activity on clinical scores as well as protection from pathological changes in the joints compared to anti-TNF-α or anti-Ang2 treatment alone.  Combination treatment provided a greater effect on inflammation/pannus formation and inflammatory cell infiltrates as well as on osteolysis and periosteal proliferation.  CD31 staining revealed decreased vascularity in the synovium of combination treated mice with a concomitant decrease in macrophage and ostoeclast infiltration.  MRI analysis of the bone surface of the joints revealed augmented protection from damage (cortical bone roughness) that is observed in this model as a result of the ongoing tenosynovitis.

Conclusion:  These data suggest that the enhanced activity of combined anti-Ang2 and anti-TNF-α treatment is due to a greater effect in decreasing vascularity in the synovium which results in decreased infiltrating inflammatory cells, as well as osteoclasts, leading to decreased bone damage in the joint.


Disclosure:

B. Naiman,

MedImmune, LLC,

3;

S. Turman,

MedImmune, LLC,

3;

W. Iverson,

MedImmune, LLC,

3;

R. Herbst,

MedImmune, LLC,

3;

T. Mustelin,

MedImmune, LLC,

3;

J. Connor,

MedImmune, LLC,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neutralization-of-angiopoietin-2-enhances-the-efficacy-of-anti-tumor-necrosis-factor-alpha-treatment-in-a-mouse-model-of-rheumatoid-arthritis-by-decreasing-cellular-infiltration-into-the-joint-and-pro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology